GlobeNewswire by notified

Corre Energy Expands Project Operations to North America

Share

NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Incentives for Energy Storage Projects in the US and Canada Offer a Unique Opportunity to Accelerate Decarbonization of North American Power Generation.

Corre Energy B.V. has expanded its energy storage project development operations into the United States and Canada. Corre Energy US Development Company LLC, a subsidiary of Corre Energy B.V., has been formally launched to source and develop utility-scale compressed air energy storage (CAES) projects across North America.

CAES is a commercially proven technology that can use renewable energy to compress air into underground salt caverns when power demand and prices are low. This energy is later released to the grid to increase supply when demand and prices are higher, enhancing the stability, reliability, and security of the network. When combustion of green hydrogen is included as part of the CAES plant’s technical design, the electricity it supplies has a zero-carbon footprint.

The US Department of Energy ranks CAES1 as the lowest cost long duration energy storage technology. The relatively inexpensive nature of the physical hedge provided to Corre Energy’s customers allows them to ‘time shift’ the variable energy they produce and enhance the profitability of their renewable assets. In this way, CAES facilities can support the more rapid deployment of renewable generation assets across North America, accelerating the decarbonization of the generation fleet.

In return for allowing renewable generators to store energy in its CAES plants and discharge that energy when its value is highest, Corre Energy will typically charge a set fee and share in the upside revenue earned by its customers, under what is termed an “offtake agreement.”

Keith McGrane, Chief Executive Officer of Corre Energy, commented: “Last month we signed binding commercial terms for a 15-year offtake agreement with Eneco, a leading renewable energy supplier in the Netherlands, for the entire multi-day storage capacity of ZW1, our 320-megawatt project. That agreement confirms the attractiveness of our business model and will support development of a project portfolio in North America.” McGrane added: “As the market leader for long duration energy storage projects in Europe, we look forward to transferring our knowhow into the US and Canada. Our North American operations will also provide opportunities for investors mainly focused on the North American market to participate in financing the debt and equity requirements of our North American subsidiary and its CAES projects.”

Chet Lyons, a pioneer in the energy storage industry, has been named president of Corre Energy US Development Company LLC. Lyons played an instrumental role in developing and commercializing merchant-based energy storage projects to perform frequency regulation ancillary services in the United States, Canada, and globally.

Lyons commented: “The success of Corre Energy B.V. in Europe and new once-in-a-generation government incentives for long duration energy storage projects in both the US and Canada make this the perfect time to build our North American project portfolio.” Lyons added: “Investment Tax Credits of 30 to 40 percent of total project costs and Production Tax Credits for the use of hydrogen will have a beneficial impact on project economics and can make our projects carbon free, enabling us to play a key role in the decarbonization of North American power generation.”

1 R. Baxter, et. al., “2022 Grid Energy Storage Technology Cost and Performance Assessment,” US Department of Energy, Technical Report Publication No. PNNL 33283, August 2022.

About Corre Energy
Corre Energy B.V. is headquartered in the Netherlands and listed on the Euronext Growth Exchange in Dublin (CORRE). Corre Energy designs, develops, constructs, and operates utility-scale Long Duration Energy Storage (LDES) projects in Europe and is developing a project pipeline in North America. Through our project development activities, Corre Energy is working to accelerate the global transition to net zero, while enhancing the security and flexibility of large-scale energy systems.

In North America, project development is done by Corre Energy US Development Company LLC, headquartered in Boston, Massachusetts.

For further information please contact:

European operations:
IR@corre.energy

North American operations:
Chet Lyons, President
Corre Energy US Development Company LLC
Email: chet.lyons@corre.energy
M: 978-930-0760

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ING announces share buyback programme of up to €2.5 billion2.5.2024 07:03:00 CEST | Press release

ING announces share buyback programme of up to €2.5 billion ING announced today a share buyback programme under which it plans to repurchase ordinary shares of ING Groep N.V., for a maximum total amount of €2.5 billion. The purpose of the share buyback programme is to converge our CET1 ratio towards our target of around 12.5%. ING Group’s CET1 ratio was 14.8% at the end of the first quarter of 2024, which is well above the prevailing CET1 ratio requirement of 10.94%. The share buyback programme will have an impact of approximately 77 bps on our CET1 ratio. The programme will commence on 2 May 2024 and is expected to end no later than 29 October 2024. The ECB has approved the programme, which will be executed in compliance with the Market Abuse Regulation and within the limitations of the existing authority to acquire a maximum of 20% of the issued shares as granted by the general meeting of shareholders on 22 April 2024. ING has entered a non-discretionary arrangement with a financial

CEX.IO Launches Mastercard-branded Crypto Debit Card2.5.2024 07:00:00 CEST | Press release

The new product enables registered users in the EEA to make everyday payments with their crypto holdings, and integrates seamlessly with CEX.IO App. VILNIUS, May 02, 2024 (GLOBE NEWSWIRE) -- CEX.IO, a global ecosystem working to bridge the worlds of crypto and traditional finance, announces the debut of CEX.IO Card, a debit card that empowers users to seamlessly spend their crypto assets on everyday purchases. This innovative product marks a pivotal step forward in CEX.IO’s mission to simplify crypto adoption, and bring the benefits of decentralized finance to the masses. The CEX.IO Card seamlessly integrates into users’ existing spending habits, allowing them to effortlessly make purchases with millions of merchants who accept Mastercard, in over 150 countries. Users can fund their cards via a variety of accessible methods, including bank transfers, as well as fiat and crypto deposits. In addition, they may set ranked priorities for their preferred methods, ensuring they always have a

ONWARD® Medical Convocation of the 2024 Annual General Meeting of Shareholders and Proposed Resolutions2.5.2024 07:00:00 CEST | Press release

EINDHOVEN, the Netherlands, May 02, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today has convened the 2024 Annual General Meeting of Shareholders (AGM), which will include consideration of the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on June 13, 2024. The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows: Adoption of the Company’s statutory annual accounts for the financial year ended December 31, 2023, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2023 statutory accounts were filed with the Netherlands Authority for the Financial Markets (AFM) on April 25, 2024, and are posted on the Company’s website (www.ir.onwd.com) and the AFM's website (afm.nl). Imp

Biotalys Starts Field Trials for Second Biofungicide2.5.2024 07:00:00 CEST | Press release

Ghent, BELGIUM, May 02, 2024 (GLOBE NEWSWIRE) -- Biotalys (Euronext: BTLS) an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, today announced the initiation of field trials for BioFun-6, the company’s second biofungicide program under development on its AGROBODY technology platform. Kevin Helash, Chief Executive Officer of Biotalys,commented: “Moving BioFun-6 into the field is another important milestone for Biotalys, demonstrating our ability to advance a series of protein-based bioactive ingredients on our platform in concert. As our first product candidate, EVOCA™, progresses through the needed regulatory process and its commercial version EVOCA NG enters its final development stage with our partner Novonesis, we will continue to build our strong pipeline of biofungicides and bioinsecticides to help growers in their transition towards more sustainable practices.” BioFun-6 is a biofungicide targeting botrytis, powdery mil

Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations2.5.2024 07:00:00 CEST | Press release

Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a phase 3b clinical study conducted in close to real-life conditions7-10 Paris, May 2, 2024. Beyfortus reduced respiratory syncytial virus (RSV) hospitalizations by 82% (95% CI: 65.6 to 90.2) in infants under 6 months of age, compared to infants who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet. These results, from the first RSV season after Beyfortus’ introduction, are part of the three-year NIRSE-GAL study conducted in Galicia, Spain un

HiddenA line styled icon from Orion Icon Library.Eye